Altimmune, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Altimmune, Inc. on September 13, 2018. The filing reports corporate governance actions taken on the same date regarding the Company's capital structure.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate structural changes rather than financial performance.
Material Changes
- Reverse Stock Split: The Company effected a one-for-thirty (1:30) reverse split of its outstanding common stock. This action reduced the number of outstanding shares from approximately 43 million to approximately 1.4 million.
- Effective Date: The reverse split became effective after the close of market on September 13, 2018. Trading on The Nasdaq Global Market began on a split-adjusted basis on September 14, 2018.
- Authorized Shares Increase: The Company increased its authorized common stock from 100,000,000 to 200,000,000 shares.
- Authorized Shares Adjustment: The number of authorized shares was not adjusted downward as a result of the reverse split.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on financial outlook, specific risks, contingencies, or unusual items beyond the structural changes described.
Key Facts for Investor Verification
- Verify the post-split share count of approximately 1.4 million shares.
- Confirm the new authorized share limit of 200,000,000.
- Check trading activity on The Nasdaq Global Market starting September 14, 2018, for split-adjusted pricing.
- Review the attached Certificates of Amendment (Exhibits 3.1 and 3.2) for legal specifics.